KP 102 - Kinetek Pharmaceuticals

Drug Profile

KP 102 - Kinetek Pharmaceuticals

Latest Information Update: 08 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kinetek Pharmaceuticals
  • Class Organometallic compounds; Small molecules; Vanadium compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 05 Feb 2003 KP 102 is available for licensing (
  • 05 Feb 2003 Suspended - Phase-I for Type-2 diabetes mellitus in United Kingdom (PO)
  • 02 Sep 1999 Kinetek is seeking strategic partners for its diabetes programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top